FDA inspection of Lupin (Sep 29, Oct 10, 2025) yielded one observation; Lupin will promptly respond within the regulatory timeline.

• Inspection spanned two weeks, concluding on October 10, 2025, with a single regulatory observation noted.
• Lupin pledges to address the FDA’s findings promptly, ensuring compliance across its global pharmaceutical operations worldwide.
• The company, headquartered in Mumbai, distributes generic, complex, biotech products, and APIs to over 100 markets.